Daniel A Barocas
Overview
Explore the profile of Daniel A Barocas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
202
Citations
3659
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barocas D, Lotan Y, Matulewicz R, Raman J, Westerman M, Kirkby E, et al.
J Urol
. 2025 Feb;
:101097JU0000000000004490.
PMID: 40013563
Purpose: In 2023 the American Urological Association (AUA) in collaboration with the Society for Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) requested an Update Literature Review (ULR) to incorporate...
2.
Tosoian J, Zhang Y, Meyers J, Heaton S, Siddiqui J, Xiao L, et al.
J Urol
. 2025 Jan;
:101097JU0000000000004421.
PMID: 39836866
Purpose: The 18-gene MyProstateScore 2.0 (MPS2) test was previously validated for detection of grade group ≥ 2 (GG ≥ 2) prostate cancer using post-digital rectal examination (DRE) urine. To improve...
3.
Lopez A, Al Hussein Al Awamlh B, Huang L, Zhao Z, Koyama T, Hoffman K, et al.
Urol Oncol
. 2024 Dec;
43(4):271.e19-271.e28.
PMID: 39690079
Objectives: Compare functional outcomes and treatment-related regret over 10 years in Spanish- and English-speaking Hispanic men compared to non-Hispanic men following treatment of localized prostate cancer. Methods And Materials: Data...
4.
Nguyen D, Barocas D, Zhao Z, Huang L, Koyama T, Al Hussein Ai Awamlh B, et al.
J Cancer Surviv
. 2024 Oct;
PMID: 39400687
Purpose: There is limited evidence of tobacco smoking's effect on cancer survivors' quality of life (QOL) and function. As the natural history of localized prostate cancer (PCa) is protracted, there...
5.
Lotan Y, Barocas D, Chang S, Daneshmand S, Konety B, Meeks J, et al.
Bladder Cancer
. 2024 Jul;
9(4):305-312.
PMID: 38994243
No abstract available.
6.
Robinson H, Lee S, Barocas D, Tosoian J
Prostate Cancer Prostatic Dis
. 2024 Jun;
28(1):45-55.
PMID: 38858447
Background: Recognizing the limitations of prostate-specific antigen (PSA) screening and the morbidity of prostate biopsies, several blood- and urine-based biomarkers have been proposed for pre-biopsy risk stratification. These assays aim...
7.
Barocas D, Al Hussein Al Awamlh B, Koyama T
JAMA
. 2024 Apr;
331(20):1770-1771.
PMID: 38683621
No abstract available.
8.
Al Hussein Al Awamlh B, Wallis C, Penson D, Huang L, Zhao Z, Conwill R, et al.
JAMA
. 2024 Jan;
331(4):302-317.
PMID: 38261043
Importance: Adverse outcomes associated with treatments for localized prostate cancer remain unclear. Objective: To compare rates of adverse functional outcomes between specific treatments for localized prostate cancer. Design, Setting, And...
9.
Ho M, Black A, Zargar H, Fairey A, Mertens L, Dinney C, et al.
Can Urol Assoc J
. 2023 Oct;
17(10):301-309.
PMID: 37851909
Introduction: Cisplatin-based neoadjuvant chemotherapy (NAC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). Cisplatin, however, can induce renal toxicity. Furthermore, RC is...
10.